Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model

Cardiovascular Research

Volumn 72, Issue 3, 2006, Pages 483-493

  Yang, Wei ^a,b   Ge, Junbo ^a   Liu, Hongling ^b   Zhao, Kan ^b   Liu, Xuebo ^a   Qu, Xiufen ^b   Li, Weimin ^b   Huang, Yonglin ^b   Sun, Aijun ^a   Zou, Yunzeng ^a  

^a FUDAN UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Angioplasty; Arsenic trioxide (As2O3); Restenosis; Stents

Indexed keywords

ARSENIC TRIOXIDE; PACLITAXEL; POLYLACTIC ACID;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INJURY; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILIAC ARTERY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTIMA; MALE; MORPHOMETRICS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RABBIT; RESTENOSIS; SERUM; SPECTROFLUOROMETRY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; ARSENICALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CELL CYCLE; CELL PROLIFERATION; COATED MATERIALS, BIOCOMPATIBLE; FLOW CYTOMETRY; GROWTH INHIBITORS; HYPERPLASIA; ILIAC ARTERY; MALE; MICROSCOPY, ELECTRON, SCANNING; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXIDES; PACLITAXEL; RABBITS; STENTS; TUNICA INTIMA;

EID: 33750519849     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.08.010     Document Type: Article

References (43)

1. Reidy M.A. A reassessment of arterial injury and arterial lesion formation. Lab Invest 53 (1985) 513-520
2. Clowes A.W., Reidy M.A., and Clowes M.M. Kinetic of cellular proliferation after arterial injury: I. Smooth muscle growth in the absence of endothelium. Lab Invest 49 (1983) 327-333
3. Ludbeook P.A. Coronary restenosis: its mechanisms and modification - overview. Coron Artery Dis 4 (1993) 225-228
4. Klein L.W., and Rosenblum J. Restenosis after successful percutaneous transluminal coronary angioplasty. Prog Cardiovasc Dis 32 (1990) 365-382
5. Castagna M.T., Mintz G.S., Leiboff B.O., Ahmed J.M., Mehran R., Satler L.F., et al. The contribution of mechanical problems to in-stent restenosis: an intravascular ultrasonographic analysis of 1090-consecutive in-stent restenosis lesions. Am Heart J 142 (2001) 970-974
6. Sabate M., Costa M.A., Kozuma K., Kay I.P., van der Giessen W.J., Coen V.L., et al. Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation 101 (2000) 2467-2471
7. Mak K.H., and Topol E.J. Clinical trials to prevent restenosis after percutaneous coronary revascularization. Ann N Y Acad Sci 811 (1997) 255-284
8. Brieger D., and Topol E. Local drug delivery systems and prevention of restenosis. Cardiovasc Res 35 (1997) 405-413
9. Liistro F., Stankovic G., Di Mario C., Takagi T., Chieffo A., Moshiri S., et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105 (2002) 1883-1886
10. Lemos P.A., van Mieghem C.A., Arampatzis C.A., Hoye A., Ong A.T., McFadden E., et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation 109 (2004) 2500-2502
11. Banaia S., Gertzb D., Gavishb L., Chornyc M., Perezb L.S., Lazarovichib G., et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res 64 (2004) 165-171
12. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with a stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
13. Aoki J., et al., Serruys for the TAXUS II Study Group. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II Study. Circulation 112 (2005) 3876-3883
14. Morton A.C., and Gunn J. Methotrexate eluting stents: to modify or cure?. Heart 90 (2004) 121-122
15. Zhang P., Wang S.Y., and Hu L.H. Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin J Hematol 17 (1996) 58-60
16. 3 induces NB cell apoptosis with down regulation of Bcl-2expression and modulation PML-RARa/PML proteins. Blood 88 (1996) 1052-1061
17. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278 (2003) 37832-37839
18. Kang Y.H., Yi M.J., Kim M.J., Park M.T., Bae S., Kang C.M., et al. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells:Reactive oxygen species-mediated poly (ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res 64 (2004) 8960-8967
19. Diaz Z., Colombo M., Mann K.K., Su H., Smith K.N., Bohle D.S., et al. Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood 105 (2005) 1237-1245
20. Baumgartner M., Sturlan S., Roth E., Wessner B., and Bachleitner-Hofmann T. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 112 (2004) 707-712
21. Schwartz R.S., Huber K.C., Murphy J.G., Edwards W.D., Camrud A.R., Vlietstra R.E., et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19 (1992) 267-274
22. Klugherz B.D., Llanos G., Lieuallen W., Kopia G.A., Papandreou G., Narayan P., et al. Twenty-eight-day efficacy and pharmacokinetics of the sirulimus-eluting stent. Coron Artery Dis 13 (2002) 183-188
23. Schakenraad J.M., Hardonk M.J., Feijin J., Molenaar I., and Nieuwenhuis P. Enzyme activity toward poly (l-Lactic acid) implants. J Biomed Mater Res 24 (1990) 539-545
24. Lincoff A.M., Furst J.G., Ellis S.G., Tuch R.J., and Topol E.J. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29 (1997) 808-816
25. Suganuma J., and Alexander H. Biological response of intramedullary bone to poly-l-lactic acid. J Appl Biomat 4 (1993) 13-27
26. Lemos P.A., Serruys P.W., and Sousa J.E. Drug-eluting stents: cost versus clinical benefit. Circulation 107 (2003) 3003-3007
27. O'Neill W.W., and Leon M.B. Drug-eluting stents: costs versus clinical benefit. Circulation 107 (2003) 3008-3011
28. Kereiakes D.J. Hippocrates revisited: the evidence for drug-eluting stents. Circulation 107 (2003) 3012-3014
29. Marx S.O., and Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104 (2001) 852-855
30. Kahan B.D. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2 (2001) 1903-1917
31. Edelman E.R., and Danenberg H.D. Rapamycin for cardiac transplant rejection and vasculopathy: one stone, two birds?. Circulation 108 (2003) 6-8
32. Huang S., and Houghton P.J. Mechanisms of resistance to rapamycins. Drug Resist Updat 4 (2001) 378-391
33. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., and Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3 (2003) 1-19
34. Ferlini C., Ojima I., Distefano M., Gallo D., Riva A., Morazzoni P., et al. Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr Med Chem Anti-Cancer Agents 3 (2003) 133-138
35. Braun-Dullaeus R.C., Mann M.J., and Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98 (1998) 82-89
36. Schwartz R.S., Holmes Jr. D.R., and Topol E.J. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 20 (1992) 1284-1293
37. Karas S.P., Gravanis M.B., Santorian E.C., Robinson K.A., Anderberg K.A., and King S.B. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 20 (1992) 467-474
38. Zeymer U., Fishbein M.C., Forrester J.S., and Cercek B. Proliferating cell nuclear antigen immunohistochemistry in rat aorta after balloon denudation: comparison with thymidine and bromodeoxyuridine labeling. Am J Pathol 141 (1992) 685-690
39. Schwartz R.S., Huber K.C., Murphy J.G., Edwards W.D., Camrud A.R., Vlietstra R.E., et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19 (1992) 267-274
40. Han D.K., Haudenschild C.C., Hong M.K., Tinkle B.T., Leon M.B., and Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol 147 (1995) 267-277
41. Kollum M., Kaiser S., Kinscherf R., Metz J., Kübler W., and Hehrlein C. Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Arterioscler Thromb Vasc Biol 17 (1997) 2383-2388
42. Cohen M.H., Hirschfeld S., Flamm Honig S., Ibrahim A., Johnson J.R., O'Leary J.J., et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 6 (2001) 4-11
43. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., et al. United States multicenter study of arsenic trioxide in relapsed acutepromyelocytic leukemia. J Clin Oncol 19 (2001) 3852-3860